Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial
Maria Vittoria Dieci(Istituto Oncologico Veneto), V Guarneri(Istituto Oncologico Veneto), Roberto D’Amico(University of Modena and Reggio Emilia), Melinda E. Sanders(Vanderbilt University), O Garrone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stefania Bartolini(Istituto delle Scienze Neurologiche di Bologna), PierFranco Conte(University of Padua), Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enrico Orvieto(AULSS 2 Marca Trevigiana), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Elena Bertone, Federica Miglietta(University of Padua)
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|572
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature
|The Oncologist|2015|531